Trials / Completed
CompletedNCT01259869
A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
A Phase II Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- NCIC Clinical Trials Group · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your glioblastoma multiforme.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PX-866 | 1 cycle = 8 weeks on study PX-866 - 8mg PO Daily |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2014-10-29
- Completion
- 2015-02-13
- First posted
- 2010-12-14
- Last updated
- 2023-08-22
- Results posted
- 2020-05-22
Locations
7 sites across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01259869. Inclusion in this directory is not an endorsement.